Immunoscore - For Rectal Cancer
Immunoscore® for Rectal Cancer can help identify patients with LARC who are at a low risk of relapse and may be good candidates for organ preservation. Immunoscore® is available through an Innovation Access Program while the company conducts clinical validation studies.
By providing an accurate measurement of T lymphocyte infiltration into the tumor, Immunoscore® gives healthcare providers insight into the risk of relapse.
A low or intermediate Immunoscore® means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, a high Immunoscore® means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.
Helping physicians identify candidates for Nonoperative Management (Watch and Wait) with Immunoscore® for Rectal Cancer
Management of patients with LARC is changing[1,2]. Patients who show a clinically complete response (cCR) to neoadjuvant treatment (NT) may be able to avoid total mesorectal excision (TME), a procedure which can lead to low patient quality of life[3].
But identifying the right patients for Nonoperative Management (Watch and Wait) has been difficult in the absence of a reliable biomarker predicting the risk of cancer recurrence.
A new study[4] has shown that Immunoscore® combined with imaging was able to identify very good responders to NT that could benefit from organ preservation strategy. In the "Watch and Wait" cohort, 100% success was observed in patients with Immunoscore High.
IMMUNOSCORE® PREDICTS THE CLINICAL OUTCOME OF LARC PATIENTS[4]
Patients with Immunoscore High have a good clinical outcome (5 yr disease-free survival: 89% vs 63% vs 55%).
IMMUNOSCORE® SELECTS LARC PATIENTS ELIGIBLE FOR “WATCH AND WAIT” APPROACH[4]
Patients with complete clinical response and Immunoscore High do not relapse and may be eligible for organ preservation.
5 YR DISEASE-FREE SURVIVAL OF PATIENTS TREATED WITH CRT AND RADICAL SURGERY BY IMMUNOSCORE[4] :
- 89% with Immunoscore High
- 63% with Immunoscore Intermediate
- 55% with Immunoscore Low